Theravance Rating Lowered to Hold at Stifel Nicolaus (THRX)
Theravance (NASDAQ:THRX) was downgraded by equities research analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, TheFlyOnTheWall.com reports. They currently have a $37.86 target price on the stock. Stifel Nicolaus’ price target indicates a potential upside of 43.41% from the company’s current price. The analysts noted that the move was a valuation call.
Shares of Theravance (NASDAQ:THRX) traded down 2.46% during mid-day trading on Thursday, hitting $25.75. The stock had a trading volume of 466,643 shares. Theravance has a 1-year low of $20.2337 and a 1-year high of $34.6172. The stock’s 50-day moving average is $22.67 and its 200-day moving average is $26.80. The company’s market cap is $2.900 billion.
Theravance (NASDAQ:THRX) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.62) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.53) by $0.09. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $4.52 million. During the same quarter last year, the company posted ($0.39) earnings per share. Theravance’s revenue was down 87.3% compared to the same quarter last year. Analysts expect that Theravance will post $-1.44 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Bank of America initiated coverage on shares of Theravance in a research note on Friday, June 6th. They set a “buy” rating on the stock. Separately, analysts at Robert W. Baird downgraded shares of Theravance from an “outperform” rating to a “neutral” rating in a research note on Monday, June 2nd. They now have a $21.00 price target on the stock, down previously from $31.00. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Theravance in a research note on Wednesday, May 7th. They now have a $29.00 price target on the stock. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the stock. Theravance presently has an average rating of “Hold” and an average price target of $29.60.
Theravance, Inc (NASDAQ:THRX) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.